- Lonza has launched a Media Development Lab at its Singapore site to support early-stage media optimization and GMP scale-up readiness.
- The offering aims to reduce development risk and improve scalability through structured optimization and manufacturability insights.
Lonza has announced the launch of a Media Development Lab at its Singapore site, expanding its CDMO and contract manufacturing capabilities in bioprocessing. The new offering is designed to help customers optimize media formulations and transition more effectively into GMP manufacturing while reducing scale-up risks.
The initiative addresses ongoing challenges in bioprocess development, including rising costs and risks associated with late-stage reformulation and increasing process complexity. According to the company, many organizations lack structured approaches to media optimization and alignment between development and manufacturing.
The Media Development Lab applies a systematic approach to early-stage media optimization, incorporating scalability, raw material readiness, and manufacturability considerations. Using Design of Experiments, the service evaluates multiple variables to identify key performance drivers, with the aim of accelerating development timelines and minimizing unnecessary iterations.
The platform integrates access to Lonza’s proprietary media and feed libraries with manufacturing insights to support the identification of robust and scalable formulations early in development. The approach also provides structured outputs that define performance ranges and process robustness.
“Our new Media Development Lab enables us to support customers at the critical front end of their programs, shape formulation strategy, and create a natural pathway into non-GMP and GMP manufacturing.”
Michael Goetter, Head of Bioscience, Specialized Modalities at Lonza
